-
Genexine completes BLA submission for anemia treatment
26 Jan 2024 07:24 GMT
… Drug Safety (MFDS) for Efesa (efepoetin alfa), its anemia treatment … Drug Authority (BPOM) after the successful completion of phase 3 clinical trials … biotech company to complete the entire drug … scheduled.
This trial will compare Efesa with Aranesp in terms …
-
Vera Therapeutics Announces Appointment of Industry Veterans Robert Brenner, M.D. as Chief Medical Officer and William D. Turner as Chief Development Officer
08 Jan 2024 13:01 GMT
… SVP of Medical Affairs at AMAG Pharmaceuticals, contributing to … clinical programs, numerous drug application filings and the … clinical-stage biotechnology company focused on developing treatments for … trial, the design and management of Vera’s clinical trials …
-
Analyzing Amgen In Comparison To Competitors In Biotechnology Industry
25 Dec 2023 16:47 GMT
… a leader in biotechnology-based human therapeutics. Flagship drugs include red … blood cell boosters Epogen and Aranesp, immune … 5.49
0.11%
Regeneron Pharmaceuticals Inc
24.01
3.68 … 4.64
16.08%
Biomarin Pharmaceutical Inc
123.58
3.66 …
-
Chemotherapy-Induced Anemia Market to Exhibit Rapid Growth Rate During the Forecast Period (2023-2032), | DelveInsight
22 Mar 2024 07:30 GMT
… Chemotherapy-Induced Anemia Drugs Uptake and Pipeline … Chugai Pharmaceutical
r-HuEPO: Hoffmann-La Roche
Aranesp: … treatment market, visit @ Chemotherapy-Induced Anemia Clinical Trials … Induced Anemia Current Treatment and Medical Practices
10. Chemotherapy …
-
Darbepoetin Alfa (Aranesp) Global Market Research Report 2023 - ResearchAndMarkets.com
23 Oct 2023 10:45 GMT
… Darbepoetin alfa (Aranesp) is a medication used to … Aranesp, and others, plays a vital role in the treatment … National Library of Medicine in January 2023, … pharmaceutical and biotechnology company, secured approval from the US Food and Drug Administration (FDA …
-
Global Darbepoetin Alfa (Aranesp) Market Forecast 2023-2032 – Market Size, Drivers, Trends, And Competitors
19 Sep 2023 15:30 GMT
The Business Research Company's Darbepoetin Alfa (Aranesp) Global Market Report 2023 – Market Size, Trends, And Global Forecast 2023-2032
LONDON, GREATER LONDON, UK, September 19, 2023 /EINPresswire.com/ -- The "Darbepoetin Alfa ( …
-
Financial Review: TRACON Pharmaceuticals (NASDAQ:TCON) vs. Amgen (NASDAQ:AMGN)
05 Sep 2023 05:12 GMT
… Pharmaceuticals (NASDAQ:TCON – Get Free Report) are both medical … and earnings than TRACON Pharmaceuticals. TRACON Pharmaceuticals is trading at … 's disease; Aranesp to treat a lower- … in Phase II clinical trial for the treatment of mesothelioma, and …
-
FDA Drug Safety Communication: Modified dosing recommendations to improve the safe use of Erythropoiesis-Stimulating Agents (ESAs) in chronic kidney disease
14 Aug 2023 00:12 GMT
… safe use of these drugs. FDA has made these … manufacturer to conduct additional trials. FDA will update the … The ESA Medication Guide (Epogen/Procrit or Aranesp) contains … = Trial to Reduce Cardiovascular Events with Aranesp Therapy.
Treatment with ESAs …
-
Biotech firms receive $3.85 million in federal financing
10 Aug 2023 14:20 GMT
… of specialized equipment for the biotechnology sector, highlighting the teamwork … following cancer treatment medicines: GCSF (Neupogen), PEG-GCSF (Neulasta), Darbepoetin (Aranesp) and … projects that boost the local pharmaceutical industry and promote the …
-
Exploring the Growth and Evolution of the Erythropoietin Drugs Market: Trends, Challenges, and Opportunities 2030
23 Jun 2023 11:13 GMT
… and Drug Administration (FDA) and the European Medicines Agency … drugs, as they are commonly used in the treatment … drug with an extended half-life, requiring less frequent dosing. Aranesp … ., Teva Pharmaceutical Industries Ltd., Intas Pharmaceuticals, Ranbaxy …